These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 25086904)

  • 1. Should we modify the principles of risk evaluation and recurrence preventive treatment of patients with calcium oxalate stone disease in view of the etiologic importance of calcium phosphate?
    Tiselius HG
    Urolithiasis; 2015 Jan; 43 Suppl 1():47-57. PubMed ID: 25086904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic evaluation and recurrence prevention for urinary stone patients: EAU guidelines.
    Skolarikos A; Straub M; Knoll T; Sarica K; Seitz C; Petřík A; Türk C
    Eur Urol; 2015 Apr; 67(4):750-63. PubMed ID: 25454613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urolithiasis in geriatric patients.
    Usui Y; Matsuzaki S; Matsushita K; Shima M
    Tokai J Exp Clin Med; 2003 Jul; 28(2):81-7. PubMed ID: 14714833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors influencing the course of calcium oxalate stone disease.
    Tiselius HG
    Eur Urol; 1999 Nov; 36(5):363-70. PubMed ID: 10516443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elucidation of factors determining formation of calcium phosphate stones.
    Pak CY; Adams-Huet B
    J Urol; 2004 Dec; 172(6 Pt 1):2267-70. PubMed ID: 15538246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential analysis of recurrent calcium calculi by infrared spectroscopy.
    Matsuzaki S; Matsushita K; Tanikawa K; Masuda A; Matsunaga J
    Int J Urol; 1995 Sep; 2(4):235-7. PubMed ID: 8564740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between supersaturation and calcium oxalate crystallization in normals and idiopathic calcium oxalate stone formers.
    Borghi L; Guerra A; Meschi T; Briganti A; Schianchi T; Allegri F; Novarini A
    Kidney Int; 1999 Mar; 55(3):1041-50. PubMed ID: 10027942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allopurinol and thiazide effects on new urinary stone formed after discontinued therapy in patients with urinary stones.
    Kohri K; Kodama M; Katayama Y; Ishikawa Y; Takada M; Kataoka K; Katoh Y; Iguchi M; Kurita T
    Urology; 1990 Oct; 36(4):309-14. PubMed ID: 2219608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is precipitation of calcium phosphate an important factor for the development of calcium oxalate stones in the urinary tract?
    Tiselius HG
    Front Biosci; 2003 May; 8():s326-32. PubMed ID: 12700064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conversion of calcium oxalate to calcium phosphate with recurrent stone episodes.
    Mandel N; Mandel I; Fryjoff K; Rejniak T; Mandel G
    J Urol; 2003 Jun; 169(6):2026-9. PubMed ID: 12771710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upper urinary tract stone compositions: the role of age and gender.
    Wang S; Zhang Y; Zhang X; Tang Y; Li J
    Int Braz J Urol; 2020; 46(1):70-80. PubMed ID: 31851461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of pH on the risk of calcium oxalate crystallization in urine.
    Berg C; Tiselius HG
    Eur Urol; 1986; 12(1):59-61. PubMed ID: 3948899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of a single evening dose of alkaline citrate on urine composition and calcium stone formation.
    Berg C; Larsson L; Tiselius HG
    J Urol; 1992 Sep; 148(3 Pt 2):979-85. PubMed ID: 1507355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of dietary intervention on urinary risk factors for stone formation in recurrent calcium oxalate stone patients.
    Siener R; Schade N; Nicolay C; von Unruh GE; Hesse A
    J Urol; 2005 May; 173(5):1601-5. PubMed ID: 15821507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphate treatment of recurrent calcium stone disease.
    Heyburn PJ; Robertson WG; Peacock M
    Nephron; 1982; 32(4):314-9. PubMed ID: 7167209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Possibilities for preventing recurrent calcium stone formation: principles for the metabolic evaluation of patients with calcium stone disease.
    Tiselius HG;
    BJU Int; 2001 Jul; 88(2):158-68. PubMed ID: 11446874
    [No Abstract]   [Full Text] [Related]  

  • 17. [Clinical characteristics of urolithiasis with stone analysis conducted over a 26-year period].
    Okuyama M; Yamaguchi S; Kita M; Kato Y; Hashimoto H; Kakizaki H; Wada N; Fujisawa M; Niibori D
    Nihon Hinyokika Gakkai Zasshi; 2007 Jan; 98(1):9-16. PubMed ID: 17302289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanouric acid or nanocalcium phosphate as central nidus to induce calcium oxalate stone formation: a high-resolution transmission electron microscopy study on urinary nanocrystallites.
    Gao J; Xue JF; Xu M; Gui BS; Wang FX; Ouyang JM
    Int J Nanomedicine; 2014; 9():4399-409. PubMed ID: 25258530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of the urinary calcium in the growth of calcium stone.
    Murayama T; Sakai N; Takano T; Yamada T
    Hinyokika Kiyo; 2004 Jul; 50(7):451-5. PubMed ID: 15334887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A hypothesis of calcium stone formation: an interpretation of stone research during the past decades.
    Tiselius HG
    Urol Res; 2011 Aug; 39(4):231-43. PubMed ID: 21246193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.